mercredi 30 mai 2018

Onco Actu du 30 mai 2018

1. Biologie

Looking beyond mutations, researchers take a new approach to an old oncogene [Broad Institute]

2. Etiologie

UNC Lineberger researchers show how viral protein helps drive cancer [UNC]

4.2 Dép., diag. & prono. - Génome

DNA Website Had Unwitting Role in Golden State Manhunt [Bloomberg]

5. Traitements

Once quickly lethal and still humbling, multiple myeloma may be in a ‘golden age’ of treatment [STAT]

5.1 Traitements - Pré-clinique

Novel RNA-modifying tool corrects genetic diseases, including driver of triple-negative breast cancer [Scripps Research Institute]

Experimental Cancer Drug Metarrestin Targets Metastatic Tumors [NCI]

Unexpected efficacy against aggressive cancers [TUM]

Anti-inflammatory strategy stops aggressive childhood cancer [Karolinska Institutet]

5.10 Traitements - Essais

Trial to test new treatment combination for children and adults with leukaemia [Cancer Research UK]

Are Big Clinical Trials Relevant? Researchers Disagree [Wall Street Journal]

5.12.2 Immunothérapies - CAR-T

Research Suggests How A Common, Serious Side-Effect Of CAR T-Cell Therapy May Be Preventable [Forbes]

Cancer Cell Therapy Trials Spike in Last Six Months, New Report Finds [RAPS]

5.12.3 Immunothérapies-combinaisons

Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results [Xconomy]

Immuno-oncology researchers seek to build smart drug combos [Novartis]

Genmab takes a hit after J&J sounds retreat on cancer combos, as patient deaths force researches to scrap trials [EndPoints]

5.12.5 Immunothérapies - Pharma

Roche's Tecentriq grabs badly needed lung cancer win to keep Keytruda in its sights [FiercePharma]

5.12.7 Immunothérapies - vaccins

Brain cancer vaccine could extend lives of patients by years [The Guardian]

European cancer vaccine startup Nouscom poaches Pfizer I-O executive [FierceBiotech]

5.2 Pharma

FDA starts speedy review of Loxo’s site-agnostic cancer drug larotrectinib [FierceBiotech]

Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX® (cabozantinib) in Previously Treated Advanced Hepatocellular Carcinoma [Exelixis]

Pfizer's Xalkori picks up FDA 'breakthrough' tags in lung cancer, lymphoma [FiercePharma]

Pfizer’s XALKORI® (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications [Pfizer]

ASCO looming, Loxo, Bayer line up a quick shot at FDA OK for their groundbreaking approach to cancer therapy [EndPoints]

U.S. FDA accepts larotrectinib New Drug Application and grants priority review [Bayer]

Loxo-Bayer cancer drug gets priority review from FDA [Reuters]

5.2.1 Pharma - Partenariats

Adaptive Biotechnologies Announces a Collaboration With Sanofi to use Adaptive’s clonoSEQ® Assay to Measure Minimal Residual Disease in Active and Future Isatuximab Multiple Myeloma Trials [Adaptive]

5.3 Traitements - FDA, EMA, NICE...

Construction of new EMA building in Amsterdam on track [EMA]

5.4 Traitements - Economie

‘Paying Twice’: A Push for Affordable Prices for Taxpayer-Funded Drugs [NY Times]

5.5.11 ASCO (SNC]

Interim Results from Clinical Trial of Immunotherapy for Glioblastoma Show Significant Clinical Benefit [Roswell Park]

6.1 Observation

Report: Ovarian Cancer Rates Continue to Decrease [ACS]

6.10.1 Politiques (USA)

The cruel sham that is federal right-to-try has passed. Let patients beware! [Respectful Insolence]

6.7 DMP, Big Data & applis

Health data provide insights into rare diseases, say panelists at Big Data in Precision Health conference [Stanford Medicine]

6.7.1 IA/bioinformatique

Nigel Hawkes: Blowing hot air on science: Theresa May misses opportunity to forward big data and AI [BMJ Blogs]

6.8 Communication

6 tips to spot cancer ‘fake news’ [Cancer Research UK]